Business
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
-- New and Updated Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation -- SEATTLE--(BUSINESS
About this update from Omeros Corporation
[{"type":"text","content":"\n-- New and Updated Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation --\n\n\n SEATTLE--(BUSINESS WIRE)--\nOmeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to OMS906, Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 65th Annual Meeting of the American Society of Hematology (ASH), to be held December 9-12, 2023 in San Diego.\n\n\nBoth abstracts were published today and are now available on the ASH website at www.hematology.org. Details of the congress presentations are found below.\n\n\nOMS906, a Novel Alternative Pathway MASP-3 Inhibitor, Normalizes Hemoglobin Levels and Increases Clone Size in Treatment-Naïve PNH Patients (Abstract #573)\nSession Name: 508. Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy from Clinical Trials\nDate: Sunday, December 10, 2023\nPodium Presentation Time: 5:00 p.m. PT\nLocation: San Diego Convention Center, Room 7\n\n\nAlternative Pathway MASP-3 Inhibitor OMS906 Effectively and Potently Inhibits Complement-Mediated Hemolysis in Preclinical Models Mechanistically Similar to Paroxysmal Nocturnal Hemoglobinuria (Abstract #4082)\nSession Name: 508. Bone Marrow Failure: Acquired: Poster III\nDate: Monday, December 11, 2023\nPresentation Time: 6:00 p.m. - 8:00 p.m. PT\nLocation: San Diego Convention Center, Halls G-H\n\n\nThe presentation materials associated with each abstract will be made available on Omeros’ website at www.omeros.com following the congress presentations.\n\n\nAbout OMS906\n\n\nOMS906 is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. The complement system plays a central role in inflammation and becomes activated as a result of tissue damage or microbial infection. Responsible for the conversion of pro-complement factor D to complement factor D, MASP-3 is believed to be the premier target in the alternative pathway – it has the lowest native circulating level and low relative clearance compared to the other alternative pathway proteins and, unlike C5 and C3 blockers, MASP-3 inhibition leaves intact the lytic arm of the classical pathway, important for fighting in...